Glial loss of the metallo β-lactamase domain containing protein, SWIP-10, induces age- and glutamate-signaling dependent, dopamine neuron degeneration

<div><p>Across phylogeny, glutamate (Glu) signaling plays a critical role in regulating neural excitability, thus supporting many complex behaviors. Perturbed synaptic and extrasynaptic Glu homeostasis in the human brain has been implicated in multiple neuropsychiatric and neurodegenerative disorders including Parkinson’s disease, where theories suggest that excitotoxic insults may accelerate a naturally occurring process of dopamine (DA) neuron degeneration. In <i>C</i>. <i>elegans</i>, mutation of the glial expressed gene, <i>swip-10</i>, results in Glu-dependent DA neuron hyperexcitation that leads to elevated DA release, triggering DA signaling-dependent motor paralysis. Here, we demonstrate that <i>swip-10</i> mutations induce premature and progressive DA neuron degeneration, with light and electron microscopy studies demonstrating the presence of dystrophic dendritic processes, as well as shrunken and/or missing cell soma. As with paralysis, DA neuron degeneration in <i>swip-10</i> mutants is rescued by glial-specific, but not DA neuron-specific expression of wildtype <i>swip-10</i>, consistent with a cell non-autonomous mechanism. Genetic studies implicate the vesicular Glu transporter VGLU-3 and the cystine/Glu exchanger homolog AAT-1 as potential sources of Glu signaling supporting DA neuron degeneration. Degeneration can be significantly suppressed by mutations in the Ca²⁺ permeable Glu receptors, <i>nmr-2</i> and <i>glr-1</i>, in genes that support intracellular Ca²⁺ signaling and Ca²⁺-dependent proteolysis, as well as genes involved in apoptotic cell death. Our studies suggest that Glu stimulation of nematode DA neurons in early larval stages, without the protective actions of SWIP-10, contributes to insults that ultimately drive DA neuron degeneration. The <i>swip-10</i> model may provide an efficient platform for the identification of molecular mechanisms that enhance risk for Parkinson’s disease and/or the identification of agents that can limit neurodegenerative disease progression.</p>